Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
| Revenue (TTM) | $132.42M |
| Gross Profit (TTM) | $90.10M |
| EBITDA | $-261.62M |
| Operating Margin | -285.00% |
| Return on Equity | -59.90% |
| Return on Assets | -16.70% |
| Revenue/Share (TTM) | $2.26 |
| Book Value | $6.60 |
| Price-to-Book | 1.38 |
| Price-to-Sales (TTM) | 6.61 |
| EV/Revenue | 5.13 |
| EV/EBITDA | -1.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -48.50% |
| Shares Outstanding | $55.38M |
| Float | $49.88M |
| % Insiders | 4.43% |
| % Institutions | 73.73% |
Volatility is currently expanding
The Endeavor® adds the fastest high-content cellular data generation to Ginkgo's around-the-clock research PORTLAND, Ore. and BOSTON, Oct. 8, 2026 /PRNewswire/ -- Araceli Biosciences and Ginkgo Bioworks (NYSE: DNA) today announced the integration of Araceli's Endeavor® high-content imaging instrument into Nebula, Ginkgo's autonomous lab in Boston.
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $11.47, moving 7.57% from the previous trading session.
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $12.5, denoting a -2.57% move from the preceding trading day.
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.58, marking a -8.43% move from the previous day.
Ginkgo Bioworks (DNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $7.06, signifying a +1% move from its prior day's close.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DNA and any ticker you trade — then tracks every position and per-strategy win rate.
